Skip to main navigation Skip to search Skip to main content

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

  • Rudolf A. de Boer*
  • , Gilles De Keulenaer
  • , Johann Bauersachs
  • , Dirk Brutsaert
  • , John G. Cleland
  • , Javier Diez
  • , Xiao Jun Du
  • , Paul Ford
  • , Frank R. Heinzel
  • , Kenneth E. Lipson
  • , Theresa McDonagh
  • , Natalia Lopez-Andres
  • , Ida G. Lunde
  • , Alexander R. Lyon
  • , Piero Pollesello
  • , Sanjay K. Prasad
  • , Carlo G. Tocchetti
  • , Manuel Mayr
  • , Joost P.G. Sluijter
  • , Thomas Thum
  • Carsten Tschöpe, Faiez Zannad, Wolfram Hubertus Zimmermann, Frank Ruschitzka, Gerasimos Filippatos, Merry L. Lindsey, Christoph Maack, Stephane Heymans
*Corresponding author for this work
  • University Medical Center Groningen
  • University of Antwerp
  • Medizinische Hochschule Hannover (MHH)
  • University of Glasgow
  • University Clinic
  • Baker IDI Heart and Diabetes Institute
  • Galecto Biotech
  • Institute for Radiology, CCM
  • FibroGen Inc.
  • King's College Hospital NHS Foundation Trust.
  • Public University of Navarra
  • University of Oslo
  • Imperial College London
  • Orion Corporation
  • RBHT Royal Brompton & Harefield NHS Foundation Trust
  • University of Naples Federico II
  • UMC University Medical Center Utrecht
  • Partner Site Munich Heart Alliance
  • CHU de Nancy
  • University Medical Center Göttingen
  • Universitatsspital Zurich
  • Attikon University Hospital
  • University of Mississippi
  • University Hospital of Würzburg
  • Maastricht University
  • KU Leuven
  • Nl-HI

Research output: Contribution to journal › Review article › peer-review

287 Citations (Scopus)

Abstract

Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction. and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.

Original languageEnglish
Pages (from-to)272-285
Number of pages14
JournalEUROPEAN JOURNAL OF HEART FAILURE
Volume21
Issue number3
DOIs
Publication statusPublished - 1 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Biomarkers
  • Fibroblast
  • Fibrosis
  • Heart failure
  • Imaging
  • Matrix
  • Prognosis

Fingerprint

Dive into the research topics of 'Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology'. Together they form a unique fingerprint.

Cite this